Harbin Jixianglong Biotech Co., Ltd.: GLP-1 import refusal records
Has FDA refused imports of GLP-1 products from Harbin Jixianglong Biotech Co., Ltd.?
Yes. FDA’s import refusal records list 2 refused shipment lines declared as made by Harbin Jixianglong Biotech Co., Ltd. (China) whose FDA product code names semaglutide and tirzepatide, from Jan 14, 2025 to Aug 6, 2025. 1 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.
- Country
- China
- City in FDA records
- Haerbin
- FEI numbers on the lines
- 3024038751
- Refused lines
- 2
- Lines with an Import Alert 66-80 API or powder code
- 1
- Drugs named in the product codes
- Semaglutide, Tirzepatide
- Refusal dates
- Jan 14, 2025 to Aug 6, 2025
The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.
Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Harbin Jixianglong Biotech Co., Ltd. is on it. Company page with the same legal name: Harbin Jixianglong Biotech Co., Ltd..
Refused shipment lines
| FDA refusal charges | Shipment ID | ||||
|---|---|---|---|---|---|
| Aug 6, 2025 | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | H77-0229191-2/13/1 |
| Jan 14, 2025 | China | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 799-5342133-7/11/1 |
FDA refusal charges on these lines
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 2 |
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 2 products naming retatrutide and tirzepatide under the labeler name “Harbin Jixianglong Biotech Co., Ltd.”, matched to this import records page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT (2).
| 84385-103 | Not given | Retatrutide | POWDER | Not given | 100 g/100g | BULK INGREDIENT | Jan 9, 2025 | None given | Dec 31, 2026 | Unfinished drugs |
| 84385-104 | Not given | Tirzepatide | POWDER | Not given | 100 g/100g | BULK INGREDIENT | May 9, 2025 | None given | Dec 31, 2027 | Unfinished drugs |
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Import Alert 66-80
- FDA Import Refusal Report bulk files
- FDA Data Dashboard: import refusals
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.
2 lines from FDA files read Nov 15, 2026.